everolimus + low-dose tacrolimus
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Highly-sensitized Kidney Transplant Recipients
Conditions
Highly-sensitized Kidney Transplant Recipients
Trial Timeline
Jun 1, 2013 → Jan 19, 2016
NCT ID
NCT01911546About everolimus + low-dose tacrolimus
everolimus + low-dose tacrolimus is a phase 2 stage product being developed by Novartis for Highly-sensitized Kidney Transplant Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT01911546. Target conditions include Highly-sensitized Kidney Transplant Recipients.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01911546 | Phase 2 | Completed |